PET monitoring of cancer therapy with 3He and 12C beams: a study with the GEANT4 toolkit.

We study the spatial distributions of beta(+)-activity produced by therapeutic beams of (3)He and (12)C ions in various tissue-like materials. The calculations were performed within a Monte Carlo model for heavy-ion therapy (MCHIT) based on the GEANT4 toolkit. The contributions from positron-emitting nuclei with T(1/2) > 10 s, namely (10,11)C, (13)N, (14,15)O, (17,18)F and (30)P, were calculated and compared with experimental data obtained during and after irradiation, where available.

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Objective: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer.

Materials And Methods: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery.